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ABSTRACT
Transarterial chemoembolization (TACE) is the standard treatment for 
intermediate stage, although the combination of TACE with sorafenib may theoretically 
benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic 
effect of sorafenib and the limitation of TACE, it is rational to combine them. Though 
the strategy of combining TACE and sorafenib has been increasingly used in patients 
with unresectable HCC but the current evidence is controversial and its clinical role 
has not been determined yet.
In first-line therapy, patients receiving sorafenib had increased overall survival 
and progression free survival. Therefore several antiangiogenic agents have entered 
clinical studies on HCC, many with negative results. This review discusses the current 
drug development for patients with HCC and role of TACE plus sorafenib.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth cause 
of cancer in the world [1].
TACE is the best treatment of intermediate stage in 
HCC in Europe and the United States [1-2] but in many 
Asian countries it’s also used in selected cases of advanced 
disease [3-6].
Despite high local disease control rate and the 
possibility to improve patients’ survival, TACE is 
considered a palliative procedure [7, 8].
Hypoxia caused by TACE can leads to the local 
release of angiogenic growth factors, this release may 
contribute to tumor recurrence or metastases and poor 
outcome [9-12].
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Figure 1: PRISMA guidelines of TACE plus Sorafenib.
Figure 2: PRISMA guidelines of antiangiogenic agents after Sorafenib.
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Table 2: Table 2 drugs on trial and results
Drug Phase Study Results
Regorafenib III mPFS: 3,1 monthsmOS: 10,6 months
Bevacizumab II mPFS: 6,9 monthsmOS: 12.4 months
Beva + gemox II mOS: 15.0 months
Sunitinib III mOS:9,8 months
Sunitinib vs sorafenib III mOS: 7,.9 months vs. 10.2 months
Brivanib II mOS: 9.7 months
BRISK-PS (Brivanib vs. placebo) III mOS: 9.4 months vs. 8.3 months
BRISK-FL (brivanib vs placebo) III mOS: 9.4 months vs. 8.3 months
Pazopanib I mTTP: 4.5 months
Tivantinib II mOS: 7.2 months vs. 3.8 months in patients with high c-met
Dovitinib (dovitinib vs sorafenib) II mOS: 8.0 months vs 8.4 monthsmTTO: 4.1 months vs 4.1months
Table 1: summarizes the main studies of sorafenib plus TACE 
Trial name/PI Results
PHASE III SPACE Trial mTTP: (S) 169 d vs. (P) 166 d p<0.072
Kudo mTTP: (S) 5.4 m vs. (P) 3.7 m p<0.252
Sansonno mTTP: (S) 9.2 m vs. (P) 4.9 m p<0.001
Hofmann mTTP: (S) 125 day vs. (P) 171 day m p=0.005
PHASE II START Trial mTTP: 9 m ORR: 53.8%
SOCRATES Trial mTTP: 16.4 m
COTSUN Trial mTTP: 7.1 m
mTTP: median time to progression; d: days; m: months; (S): sorafenib; (P): placebo; ORR: overall response rate.
Sorafenib acts through inhibition of vascular and 
endothelial growth factor receptor 2 and 3 and platelet-
derived growth factor receptor beta leading to an anti-
angiogenic effect. Molecular predictors of sorafenib 
efficacy have not yet been identified [13-17].
Therefore, the combination of TACE with sorafenib 
may theoretically benefit HCC patients.
Currently, sorafenib has been shown to significantly 
increase overall survival (OS) and progression free 
survival (PFS) in patients with BCLC stage C.
Hepatocellular carcinoma are vascular tumours and 
inhibition of angiogenesis may be represent a potential 
therapeutic target. For this reason, several antiangiogenic 
agents have studies on HCC.
This review discusses the current drug development 
for patients with HCC and the combination of TACE plus 
sorafenib.
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Figure 4: Pathway of multitarget TKI.
Figure 3: Pathway of multitarget TKI.
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MATERIALS AND METHODS
Search strategy and selection criteria
We searched on PubMed/MEDLINE and 
Clinicaltrials.gov using the following keywords: ‘‘second-
line AND hepatocellular carcinoma’’ for antiangiogenic 
study in second line and “TACE plus Sorafenib’’ or “TACE 
and Sorafenib” for sorafenib plus TACE. We use PRISMA 
guidelines (Figures 1 and 2) to identify all study.
We reviewed the references of all included articles 
to identify additional sources of data, missing articles or 
meeting abstracts. When multiple sources of data from the 
same study population were found, we relied on the data 
from the most complete peer-reviewed publication.
Sorafenib plus tace
Several studies have explored this combination 
therapy, from either retrospective series or small early-
phase studies. Moreover there is a wide heterogeneity in 
study design especially in underlying liver disease (HCV 
vs HBV), overall hepatic function (Child A vs Child 
B), BCLC stage (A vs B vs C), modality of sorafenib 
treatment (sequential vs. continuous vs. interrupted), and 
variables linked to TACE treatment.
Table 1 summarizes the main studies of sorafenib 
plus TACE.
According to the classification by Strebel et al [18], 
trials that encourage combination of TACE with sorafenib 
are divided into three main categories:
1. continuous schedule: patients are treated all the 
time with sorafenib.
2. Interrupted schedule: patients are treated with 
sorafenib only between TACE sessions.
3. Sequential schedule: the patients was treated with 
TACE followed by sorafenib.
Randomized trial
In literature there are four randomized trial.
The SPACE trial, is a phase II randomized trial that 
enrolled 307 patients [19]. Even if the primary endpoint 
was no achieved (p= 0.072), in fact the time to progression 
was similar between two groups (169 days for sorafenib 
group respect166 days for placebo group). The HR for 
overall survival was 0.898.
Kudo et al presented a double blind placebo 
controlled phase III trial. The trial was designed before 
the indication of sorafenib in first line of advanced HCC 
[20]. The study enrolled 458 patients. The study failed the 
primary endpoint, the median time to progression was of 
5.4 in the sorafenib group and 3.7 months in placebo group 
(p = 0.252). Probably, these results may be due to the fact 
that 91% had dose interruptions and 73% of patients had 
sorafenib dose reductions.
Sansonno et al, in a Italian single-center randomized 
study enrolled 62 patients [21]. Patients received sorafenib 
or placebo after conventional TACE. The trial was positive 
with a median time to progression of 9.2 months in the 
sorafenib group vs 4.9 months in the placebo group (p < 
0.001).
In the study of Hofmann et al [22], fifty patients 
were randomly in double-blinded and treated with TACE 
plus Sorafenib or placebo. The trial was negative, the HR 
of time to progression was 1.106 (95% CI: 0.387, 3.162). 
The results was negative also for objective response rate, 
disease control rate, progression free survival and time to 
liver-transplant.
Recently, a meta-analysis that included all four 
studies show that TACE plus sorafenib may have superiority 
of TACE only in terms of time to progression (HR=0.77, 
P=0.005) but not for OS (HR=0.97, P=0.828), ORR 
(RR=1.20, P=0.257) and DCR (RR=1.04, P=0.568) [23].
Phase II trial
START trial [24] enrolled 192 Asian patients. 
81.2% of patients were with HBV. Patients received 
sorafenib with interrupted schedule (3 days before and 
after conventional TACE). 52 patients had grade 3/4 
adverse events, only 8.1% discontinued sorafenib for 
toxicities with no treatment-related deaths. Median time to 
progression was 9 months with a 53.8% of response rate.
SOCRATES trial [25], a multicenter single-arm trial 
enrolled 43 patients. Median overall survival was 20.1 
months with time to progression was 16.4 months. The 
authors value with EASL criteria the response and showed 
74,4% of disease control rate.
COTSUN trial [26], a single-arm enrolled 50 patients 
with interrupted schedule with median time to progression 
was 7.1 months, many patients have discontinued sorafenib 
for thrombocytopenia and skin toxicity.
Another phase II study enrolled 35 patients [27]. 
The study reported disease control rate of 95% according 
to RECIST criteria with 40 dose interruptions and 25 dose 
reductions for sorafenib. In the paper the authors did not 
report the data of time to progression, progression free 
survival or overall survival.
Ongoing study
The SELECT trial [28] is an ongoing prospective 
multicenter randomized study. Aims of the study was 
to evaluate efficacy and safety of continued schedule of 
sorafenib combined with conventional TACE.
The second trial is a phase III randomized trial 
[29, 30] with intermediate HCC and Child-Pugh score 
A-B7 with continued schedule. The primary endpoint is 
progression free survival, secondary endpoints are overall 
survival and pattern of treatment failure (extrahepatic vs 
intrahepatic).
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The last is an ongoing phase IV non-randomized 
study [31] that evaluating the benefits of traditional 
TACE plus sequential sorafenib with sequential schedule 
(sorafenib started 2-4 weeks after) versus TACE alone 
in this setting of patients with child-Pugh score A. The 
primary endpoint is overall survival and secondary 
endpoint is time to progression.
Antiangiogenic agents after sorafenib
Several antiangiogenic agents have entered clinical 
studies in HCC as summarized in Table 2, in Figures 3 and 
4 show the pattern of new drug.
Regorafenib
Regorafenib show that can be improved overall 
survival in HCC patients in the RESORCE trial [32].
In the RESORCE trial a total of 573 patients were 
randomized (patients were randomized 2:1 to receive 
regorafenib or placebo) after failure of first line with 
sorafenib. Regorafenib reduce 38% in the risk of death 
(p <0.001) and median overall survival was 10.6 months 
in patients treated with regorafenib versus 7.8 months in 
patients treated with placebo. Regorafenib reduced by 54% 
the risk of progression or death with median progression 
free survival of the patients treated with regorafenib was 
3.1 vs 1.5 months for patients treatment with placebo 
(time to progression was 3.2 vs 1.5 respectivily). Disease 
controll rate was 65.2% for regorafenib vs 36.1% for 
placebo (p<0.001).
Actualy regorafenib in second line after progression 
of Sorafenib is the standard of care.
Bevacizumab
Several studies have explored the use of 
bevacizumab as a single agent or in combination with 
other agents.
Bevacizumab was tested in two study as a single 
agent. In the first study published by Siegel et al [33], 
the median progression free survival was 6.9 months and 
median overall survival was 12.4 months. In the second 
study [34] 13.9% patients on 43 had partial response and 
42% had disease control rate at 16 weeks.
Bevacizumab was tested in combination with 
erlotinib in two phase II studies [35, 36].
Kaseb et al. [35] enrolled 59 patients. 24% achieved 
partial response, 56% had stable disease, 10% progressed 
(overall survival was 13.7 months and PFS was 7.2 
months). In the second study Yau et al [36] enrolled 10 
patients with median time to progression of 1.81 months 
and overall survival was 4.37 months.
In conclusion, these studies demonstrated evidence 
of antitumor activity of Bevacizumab in HCC. Future 
prospective studies will tell us the real effectiveness of 
this drug.
Sunitinib
Cheng et al. [37] completed a randomized phase III 
trial comparing sunitinib with sorafenib.
1,074 patients were randomized with median overall 
survival of 7.9 in the sunitinib arm vs. 10.2 months in the 
sorafenib arm (P=0.0014).
For these reasons the authors concluded that overall 
survival with sorafenib was significantly higher than with 
sunitinib.
Brivanib
Brivanib is a tyrosine kinase inhibitor that shows 
selective inhibition of VEGFR and fibroblast growth 
factor receptor.
The antitumor activity of brivanib in patients with 
HCC was tested in three phase III studies.
In the BRISK-FL study [38] was tested in first-line. 
Median overall survival, time to progression and disease 
control rate were similar between sorafenib and brivanib.
In the BRISK-PS study [39] brivanib was tested 
in 395 patients with advanced HCC who progressed or 
were intolerant to sorafenib. Median overall survival was 
similar between brivanib and placebo arms (9.4 months for 
brivanib and 8.2 months for placebo, HR 0.89; P = .3307), 
but brivanib was associated with a longer median time to 
progression than sorafenib (4.2 months for brivanib and 
2.7 months for placebo HR: 0.56 P < .001).
The last (BRISK-APS) is an ongoing study [40] 
enrolling second-line patients from the Asian-Pacific 
region.
Linifanib
Linifanib is an orally active, potent and selective 
inhibitor of VEGFR and PDGFR.
A phase III trial [41] randomized 1,035 patients 
with median overall survival of 9.1 months in the linifanib 
arm and 9.8 months in the sorafenib arm. Linifanib and 
sorafenib resulted in similar overall surival associated with 
more toxicity for linifanib arms.
Pazopanib
Pazopanib is an orally inhibitor of VEGFR, PDGFR 
and c-Hit.
A phase I dose-escalating study of pazopanib [42] 
was conducted to determine the maximum tolerated dose, 
it was defined at 600 mg once daily. No phase II trial has 
been programmed.
Tivantinib
Tivantinib is a selective inhibitor of MET.
In a phase II trial [43] 107 patients with 
unresectable HCC progressed after first-line treatment 
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or were intolerant. Patients were randomized to receive 
either 360 mg or 240 mg of tivantinib twice daily or 
placebo.
Median OS was 7.2 months for patients treated 
with tivantinib compared with 3.8 months for patients 
treated with placebo (HR: 0.38, p = 0.01). Median time 
to progression was 2.9 months for patients treated with 
tivantinib compared 1.5 months for patients treated 
with placebo (HR 0:43, p = 0.03). In this study MET 
level was predictive of time to progression and overall 
survival.
A global randomized phase III study comparing 
the clinical activity of tivantinib versus best supportive 
care in patients with hepatocellular carcinoma in second-
line therapy will be presented at ASCO 2017 but a press 
release announced that the study did not meet the primary 
endpoint.
Cabozantinib
Cabozantinib is a dual MET/VEGFR-2 inhibitor. 
It was tested in second-line therapy for hepatocellular 
carcinoma in a phase II randomized study [44], with 41 
patients enrolled, 4.4 months median PFS and 15.1 months 
median overall survival. A global randomized phase III 
study is ongoing.
Ramucirumab
A phase II study [45] of 42 patients with advanced 
hepatocellular carcinoma showed that ramucirumab in 
first-line produced a 50% DCR and a median PFS of 4.3 
months.
In the REACH study thee results show that the 
HR for overall survival was 0.866 (p = 0.1391); overall 
survival was 9.2 months and progression free survival was 
2.8 months for the ramucirumab arm versus 7.6 months 
for overall surivival and 2.1 months for progression free 
survival in the placebo arm.
A subgroup analysis show that patients with high 
baseline alpha-fetoprotein (≥400 ng/mL) have a median 
OS of 7.8 months for ramucirumab versus 4.2 months for 
placebo, HR was 0.67 (p = 0.0059) with [46].
This suggests that elevated baseline AFP may be a 
predictive marker for survival benefit to ramucirumab, and 
it is now the basis for a biomarker selected Phase III study 
(REACH-2) in the same setting.
Cediranib
Cediranib and vatalanib are oral inhibitors of VEGF 
receptor tyrosine kinase. A phase II study was published 
[47] with cediranib, but with no responses to the drug. 
Median OS was 5.8 months. No phase III trial has been 
programmed.
Dovitinib
Dovinitib is a potent tyrosine kinase inhibitor 
targeting at FGFR, VEGFR, PDGFR and c-kit.
In preclinical study dovinitib showed an activity in 
HCC [48].
A randomized phase II study [49] comparing the 
clinical activity of dovitinib versus sorafenib. In this trial 
dovitinib and sorafenib resulted in similar OS and TTP. No 
phase 3 trial has been planned.
CONCLUSIONS
Over the last decade, the progress in managing 
advanced liver cancers has been slow for three many 
reasons. First of all, we have probably failed in the 
planning phase of clinical trials. Published data show 
a wide heterogeneity in the study design, ethnicity of 
patients enrolled, underlying liver disease (HCV vs. 
HBV), grade of liver decompensation (Child A vs. Child 
B), BCLC stage (A vs. B vs. C often mixed in variable 
proportions), presence of patients with vascular invasion 
or metastatic disease, modality of sorafenib treatment 
(sequential vs. continuous vs. interrupted), type of TACE 
(conventional vs DEB-TACE), type of chemotherapy, 
number of drugs delivered (single agent vs. combination), 
dose of chemotherapy, use of embolizing materials, 
number of procedures administered, and schedule (on-
demand vs. pre-planned). Consequently, the results of 
the studies are contrasting. Secondly, we lack effective 
drug. Thirdly, we did not properly plan effective strategies 
with treatment combinations or sequences. Combination 
therapy may provide clinical benefit for patients with 
HCC but subjects selection is imperative to avoid 
unacceptable toxicities or even harm (for example liver 
decompensation).
A better understanding of the biology of HCC, the 
variables that could predict response to sorafenib, and 
the mechanisms by which anti-angiogenic agents work 
in concert with conventional chemotherapeutic agents 
used in TACE, will be critical to design the definitive 
trial on the combination treatment. Post hoc analysis of 
the SHARP trial show that low baseline concentrations of 
angiopoietin-2 and VEGF-A were associated with better 
OS [50, 51]. Casadei Gardini et al and Scartozzi et al 
have studied the role of polymorphisms and response to 
sorafenib. This two study showed that VEGF-A, VEGF-C 
and eNOS polymorphisms were independent factors of 
PFS and OS [52, 53].
We probably would have different therapeutic 
options in the first and second line of HCC treatment in 
the next five years, changing the scenario for this disease. 
As previously reported in the latest years for the kidney 
tumor we could have instead of few therapeutic options 
several active compounds.
Oncotarget66706www.impactjournals.com/oncotarget
Many promising drugs in phase II studies failed 
in phase III trials. There are multiple reasons for these 
failures. The most important is the faulty study designs, in 
particular stratification at the time of randomization.
In the future we have to identify new meccanism 
of hepatocarcinogenesis to study new treatment approach.
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